Omalizumab — an antibody against immunoglobulin E (IgE) — may be effective and safe for wound healing in patients with recessive…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Topline data should be available toward the end of this year for a Phase 3 clinical trial testing B-VECÂ (beremagene…
The U.S. Food and Drug Administration (FDA) has awarded Castle Creek Biosciences a research grant to support its Phase…
From sharing stories to spreading the word about epidermolysis bullosa (EB) in person and on social media, supporters are…